[go: up one dir, main page]

MA27888A1 - Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainons - Google Patents

Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainons

Info

Publication number
MA27888A1
MA27888A1 MA28678A MA28678A MA27888A1 MA 27888 A1 MA27888 A1 MA 27888A1 MA 28678 A MA28678 A MA 28678A MA 28678 A MA28678 A MA 28678A MA 27888 A1 MA27888 A1 MA 27888A1
Authority
MA
Morocco
Prior art keywords
kinase
kinase inhibitors
inhibitors based
heterocycles
chain
Prior art date
Application number
MA28678A
Other languages
English (en)
Inventor
Olga M Fryszman
Hengyuan Lang
Jiong Lan
Edcon Chang
Yunfeng Fang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34108816&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27888(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA27888A1 publication Critical patent/MA27888A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)

Abstract

L'invention concerne des inhibiteurs de la kinase p38 à base d'hétérocycles à 5 chaînons. L'invention concerne en outre des inhibiteurs de la kinase p38, notamment de la kinase p38(alpha) et p38(bêta), à base de pyrazoles et d'imidazoles. L'invention concerne par ailleurs des compositions pharmaceutiques contenant ces composés, ainsi que des méthodes d'utilisation de ces composés et de ces compositions, notamment des méthodes visant à traiter, prévenir ou améliorer un ou plusieurs symptômes de maladies et de troubles à médiation par la kinase p38 comprenant, de façon non limitative, des maladies et des troubles inflammatoires.
MA28678A 2003-06-26 2005-12-21 Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainons MA27888A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48342803P 2003-06-26 2003-06-26
US49905403P 2003-08-29 2003-08-29
US56048104P 2004-04-07 2004-04-07

Publications (1)

Publication Number Publication Date
MA27888A1 true MA27888A1 (fr) 2006-05-02

Family

ID=34108816

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28678A MA27888A1 (fr) 2003-06-26 2005-12-21 Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainons

Country Status (26)

Country Link
US (4) US7863314B2 (fr)
EP (2) EP2298743B1 (fr)
JP (1) JP4838121B2 (fr)
KR (1) KR101120857B1 (fr)
CN (1) CN1832928B (fr)
AT (1) ATE517872T1 (fr)
AU (1) AU2004259662B2 (fr)
BR (1) BRPI0411825B8 (fr)
CA (1) CA2526455C (fr)
CY (2) CY1111985T1 (fr)
DK (2) DK2298743T3 (fr)
EC (2) ECSP056206A (fr)
ES (1) ES2393950T3 (fr)
HR (2) HRP20110757T1 (fr)
IL (1) IL172182A (fr)
IS (2) IS2916B (fr)
MA (1) MA27888A1 (fr)
MX (1) MXPA05013824A (fr)
MY (1) MY158162A (fr)
NO (1) NO334947B1 (fr)
NZ (1) NZ544230A (fr)
PL (2) PL2298743T3 (fr)
PT (2) PT1641764E (fr)
SI (2) SI1641764T1 (fr)
TW (2) TWI449696B (fr)
WO (1) WO2005009973A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485657B2 (en) 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
CA2606226A1 (fr) * 2005-04-27 2006-11-02 University Of Florida Research Foundation, Inc. Materiaux et methodes permettant d'ameliorer la degradation de proteines mutantes associees avec une maladie humaine
DE102005031580A1 (de) * 2005-07-06 2007-01-11 Aicuris Gmbh & Co. Kg Substituierte Sulfolanylpyrazole und ihre Verwendung
GB0603684D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
BRPI0708974A2 (pt) 2006-03-22 2011-06-21 Hoffmann La Roche composto, composição farmacêutica, métodos de tratamento de diabetes, obesidade ou sìndrome metabólica e uso do composto
WO2007118084A2 (fr) * 2006-04-03 2007-10-18 Stowers Institute For Medical Research Compositions et méthodes pour le traitement d'une polykystose rénale
EP2079702A1 (fr) * 2006-10-30 2009-07-22 Novartis AG Dérivés de 3-amino-pyrazole-4-carboxamide utilisables comme inhibiteurs des protéines kinases
GB0621978D0 (en) * 2006-11-03 2006-12-13 Chroma Therapeutics Ltd Inhibitors of p38 mitogen-activated protein kinase
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
US20090047243A1 (en) * 2007-07-17 2009-02-19 Richard Rickles Combinations for the treatment of b-cell proliferative disorders
CA2694983A1 (fr) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Traitements de troubles proliferatifs des lymphocytes b
ES2551095T3 (es) * 2007-07-19 2015-11-16 Lundbeck, H., A/S Amidas heterocíclicas de 5 miembros y compuestos relacionados
KR20100092960A (ko) * 2007-12-21 2010-08-23 한국화학연구원 Ｈｉｖ 역전사 효소 억제제의 제조 방법
DE102008015033A1 (de) * 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
US20090281150A1 (en) * 2008-04-09 2009-11-12 Nicola Frances Bateman Compound 249
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
PT2313111E (pt) 2008-08-01 2013-12-05 Ventirx Pharmaceuticals Inc Formulações de agonista de receptor do tipo toll e seus usos
ES2545275T3 (es) 2008-11-06 2015-09-09 Ventirx Pharmaceuticals, Inc. Métodos de síntesis de derivados de benzazepinas
KR101529767B1 (ko) * 2009-08-07 2015-06-17 추가이 세이야쿠 가부시키가이샤 아미노피라졸 유도체
WO2011022509A2 (fr) 2009-08-18 2011-02-24 Ventirx Pharmaceuticals, Inc. Benzoazépines substituées comme modulateurs des récepteurs de type toll
PL2467377T3 (pl) 2009-08-18 2017-10-31 Ventirx Pharmaceuticals Inc Podstawione benzoazepiny jako modulatory receptora toll-podobnego
WO2011038261A1 (fr) * 2009-09-24 2011-03-31 Selexagen Therapeutics, Inc. Inhibiteurs hétérocycliques de la kinase
CA2789847A1 (fr) * 2010-02-15 2011-08-18 Synovo Gmbh Modulateurs de kinase pour le traitement du cancer
PT2619182T (pt) * 2010-09-21 2017-01-17 Eisai R&D Man Co Ltd Composição farmacêutica
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
EP2460519A1 (fr) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma pour la douleur du cancer des os
JP5620417B2 (ja) * 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬
US9339491B2 (en) * 2012-03-20 2016-05-17 Mereo Biopharma 1 Limited Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
US20160304466A1 (en) * 2013-12-04 2016-10-20 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
US9802920B2 (en) 2013-12-13 2017-10-31 Hoffman-La Roche Inc. Inhibitors of bruton's tyrosine kinase
CA2929747C (fr) 2013-12-13 2018-01-23 F. Hoffmann-La Roche Ag Inhibiteurs de la tyrosine kinase de bruton
JP6514645B2 (ja) 2013-12-27 2019-05-15 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
US10479780B2 (en) 2015-06-17 2019-11-19 Chugai Seiyaku Kabushiki Kaisha Aminopyrazole derivatives
EP3339305B1 (fr) * 2015-08-20 2022-05-04 Zhejiang Hisun Pharmaceutical Co., Ltd Dérivé d'indole, son procédé de préparation et son utilisation dans un médicament pharmaceutique
AU2016397046B2 (en) * 2016-03-08 2022-05-12 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
WO2017153702A1 (fr) 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Régime posologique pour le traitement d'exacerbations aiguës de la broncho-pneumopathie chronique obstructive
GB201612238D0 (en) * 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0 (en) * 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
WO2018059533A1 (fr) * 2016-09-29 2018-04-05 南京明德新药研发股份有限公司 Inhibiteur de la p38α mapk kinase, son procédé de préparation et son utilisation
WO2018109667A1 (fr) 2016-12-15 2018-06-21 Nestec Sa Compositions et procédés de modulation des globules blancs ou des neutrophiles chez un animal de compagnie
EP3692144A1 (fr) 2017-10-05 2020-08-12 Fulcrum Therapeutics, Inc. Utilisation d'inhibiteurs de p38 pour réduire l'expression de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3585382T (pt) 2017-12-11 2021-08-19 Mereo Biopharma 1 Ltd Utilização de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-n-ciclopropil-4-metilbenzamida no tratamento de exacerbações agudas da doença pulmonar obstrutiva crónica
KR102760007B1 (ko) 2017-12-11 2025-02-03 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화의 예방 또는 감소에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
US10889548B2 (en) 2018-03-26 2021-01-12 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
EP3563848A1 (fr) * 2018-04-30 2019-11-06 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Inhibiteurs de la serpine pour le traitement des maladies à prions et de type prion
GB201815696D0 (en) 2018-09-26 2018-11-07 Mereo Biopharma 1 Ltd Synthetic method
GB201815695D0 (en) * 2018-09-26 2018-11-07 Mereo Biopharma 1 Ltd Synthetic method
GB201815699D0 (en) * 2018-09-26 2018-11-07 Mereo Biopharma 1 Ltd Synthetic method
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用
US12134611B2 (en) 2018-11-13 2024-11-05 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
ES2974842T3 (es) * 2018-11-13 2024-07-01 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp
US20210315880A1 (en) 2020-03-20 2021-10-14 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
CN112778333B (zh) * 2021-01-23 2022-07-05 中国科学院新疆理化技术研究所 一种四氢噁唑并吡啶并氮氧杂酮类衍生物及其用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1152421B (de) 1961-03-21 1963-08-08 Bayer Ag Verfahren zur Herstellung von 4-Hydroxy-pyrazolo[3, 4-b]chinolinen
JPS5111499Y2 (fr) 1971-04-22 1976-03-27
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
JPS5527916B2 (fr) 1973-02-05 1980-07-24
JPS51112341A (en) 1975-02-24 1976-10-04 Konishiroku Photo Ind Co Ltd Magenta dye image formation
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US6005109A (en) * 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
JP2862374B2 (ja) 1992-12-17 1999-03-03 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニスト活性を有するピラゾール及びピラゾロピリミジン
US6103900A (en) * 1992-12-17 2000-08-15 Pfizer Inc Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
US5514643A (en) 1993-08-16 1996-05-07 Lucky Ltd. 2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms
US5646152A (en) 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
CA2163399A1 (fr) 1994-11-24 1996-05-25 Katsuhiro Kawano Derives de la triazine, inhibiteurs de l'activite de la chymase et de la production d'oxyde nitrique
DE19518054A1 (de) 1995-03-08 1996-09-12 Hoechst Schering Agrevo Gmbh N-Arylpyrazolketone und deren Derivate, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
BR9706973A (pt) 1996-01-11 1999-04-06 Smithkline Beecham Corp Novos compostos de imidazol substituídos
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
CZ225699A3 (cs) 1996-12-23 2000-09-13 Du Pont Pharmaceuticals Company Dusíkaté heteroaromatické sloučeniny jako inhibitory faktoru Xa
EP0983260A2 (fr) 1997-05-22 2000-03-08 G.D. Searle & Co. PYRAZOLES 3(5)-HETEROARYL SUBSTITUEES UTILISEES COMME INHIBITEURS DE KINASE p38
US6087496A (en) 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
EP1019396A1 (fr) 1997-07-02 2000-07-19 SmithKline Beecham Corporation Nouveaux imidazoles cycloalkyle-substitues
ES2267873T3 (es) 1997-10-27 2007-03-16 Agouron Pharmaceuticals, Inc. Derivados de 4-aminotiazol, su preparacion y uso como inhibidores de kinasas dependientes de ciclina.
US20020156114A1 (en) 1998-05-05 2002-10-24 Goldstein David Michael Pyrazole derivatives - p38 MAP kinase inhibitors
WO1999057101A1 (fr) * 1998-05-05 1999-11-11 F. Hoffmann-La Roche Ag Derives de pyrazole tenant lieu d'inhibiteurs de p.38 map kinase
US6376527B1 (en) 1998-05-05 2002-04-23 Syntex (U.S.A.) Llc Pyrazole derivatives-p38 map kinase inhibitors
US6316466B1 (en) 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
US6130235A (en) 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2000012074A2 (fr) 1998-08-28 2000-03-09 Scios Inc. INHIBITEURS DE p38-α KINASE
CA2348234A1 (fr) 1998-10-29 2000-05-11 Chunjian Liu Composes derives d'un noyau amine inhibiteurs de l'enzyme impdh
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
CN1348370A (zh) 1999-04-15 2002-05-08 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
ATE288915T1 (de) 1999-11-10 2005-02-15 Ortho Mcneil Pharm Inc Substituierte 2-aryl-3-(heteroaryl)-imidazo(1,2- alpha)pyrimidine und ihren verwandten arzneimittel und verfahren
WO2001056567A1 (fr) 2000-02-04 2001-08-09 Novo Nordisk A/S Derives de 2,4-diaminothiazole
WO2002024200A1 (fr) 2000-09-21 2002-03-28 Bristol-Myers Squibb Company Derives d'azole substitues en tant qu'inhibiteurs du facteur de liberation de la corticotropine
NZ525334A (en) 2000-11-17 2005-07-29 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
WO2002057101A2 (fr) 2001-01-17 2002-07-25 Boyean Kim Pare-soleil avec appareils de bureau
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
MXPA03010269A (es) 2001-05-11 2004-05-05 Vertex Pharma Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38.
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124928D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
DE602004025504D1 (de) * 2003-12-23 2010-03-25 Novartis Ag Bicyclische heterocyclische p-38-kinase-inhibitoren
JP2007084437A (ja) 2003-12-26 2007-04-05 Dai Ichi Seiyaku Co Ltd アミノアルキルピラゾール誘導体

Also Published As

Publication number Publication date
NZ544230A (en) 2009-07-31
PT1641764E (pt) 2011-10-27
IS2984B (is) 2017-09-15
MY158162A (en) 2016-09-15
TW200510328A (en) 2005-03-16
KR20060024813A (ko) 2006-03-17
CY1111985T1 (el) 2015-11-04
HRP20110757T1 (hr) 2011-11-30
CN1832928B (zh) 2012-07-04
ATE517872T1 (de) 2011-08-15
CN1832928A (zh) 2006-09-13
HK1149764A1 (en) 2011-10-14
EP1641764B1 (fr) 2011-07-27
IS2916B (is) 2014-12-15
DK1641764T3 (da) 2011-11-21
ES2393950T3 (es) 2013-01-02
PT2298743E (pt) 2012-12-04
EP1641764A1 (fr) 2006-04-05
US7863314B2 (en) 2011-01-04
US8242117B2 (en) 2012-08-14
ECSP12006206A (es) 2012-03-30
TWI449696B (zh) 2014-08-21
AU2004259662A1 (en) 2005-02-03
CA2526455C (fr) 2012-10-09
TW201125854A (en) 2011-08-01
US20050049288A1 (en) 2005-03-03
DK2298743T3 (da) 2012-11-26
JP2007521278A (ja) 2007-08-02
US20130172352A1 (en) 2013-07-04
WO2005009973A1 (fr) 2005-02-03
CA2526455A1 (fr) 2005-02-03
AU2004259662B2 (en) 2008-08-07
CY1113313T1 (el) 2016-04-13
US8580838B2 (en) 2013-11-12
SI2298743T1 (sl) 2012-12-31
ECSP056206A (es) 2006-04-19
TWI452035B (zh) 2014-09-11
JP4838121B2 (ja) 2011-12-14
US20110071152A1 (en) 2011-03-24
IL172182A (en) 2014-07-31
US8410160B2 (en) 2013-04-02
IS8255A (is) 2006-01-23
MXPA05013824A (es) 2006-02-28
NO334947B1 (no) 2014-08-04
NO20060424L (no) 2006-03-15
BRPI0411825A (pt) 2006-08-08
PL2298743T3 (pl) 2013-02-28
HRP20120900T1 (hr) 2012-11-30
HK1088895A1 (en) 2006-11-17
BRPI0411825B1 (pt) 2018-11-06
BRPI0411825B8 (pt) 2021-05-25
IS9037A (is) 2014-01-28
KR101120857B1 (ko) 2012-04-12
PL1641764T3 (pl) 2011-12-30
SI1641764T1 (sl) 2011-11-30
EP2298743B1 (fr) 2012-08-22
US20120264801A1 (en) 2012-10-18
EP2298743A1 (fr) 2011-03-23

Similar Documents

Publication Publication Date Title
MA27888A1 (fr) Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainons
BRPI0410905A (pt) inibidores de p-38
WO2005063766A3 (fr) Inhibiteurs heterocycliques bicycliques des kinases p-38
CY1120241T1 (el) Χρησιμοποιηση εψιδινης για την παρασκευη ενος φαρμακου για τη θεραπεια διαταραχων της ομοιοστασης του σιδηρου
DK1333833T3 (da) Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme
EP1689406A4 (fr) Inhibiteurs heterocycliques de mek et methodes d'utilisation associees
IS7840A (is) 3-(3,5-díoxó-4,5-díhýdró-3H-(1,2,4)tríasín-2-ýl)-bensamíð afleiður sem P2X7-hindrar til notkunar í meðferð á bólguvaldandi sjúkdómum
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
CY2013041I2 (el) Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
UA85597C2 (ru) Четвертичные соли как антагонисты ccr2
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
WO2004072062A3 (fr) Derives d'indolylmaleimide
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
TNSN05307A1 (en) 5-membered heterocycle-based p38 kinase inhibitors
ITMI20022594A1 (it) Combinazione terapeutica per la cura dell'ipertensione.